For example, targeting receptors that are overexpressed in specific cancers, such as HER2 in breast cancer, enables direct delivery of chemotherapeutic agents to malignant cells while minimizing systemic toxicity (Krishnamurti and Silverman, 2014; Ratajczak et al., 2023). Here, ERBB2 is linked to breast carcinoma.